Stewart-Treves syndrome.

Marek Stanczyk
Marek Stanczyk
Central Clinical Hospital of Military Medical School
Magdalena Gewartowska
Magdalena Gewartowska
Military Health Service Institute

Indian J Med Res 2014 Jan;139(1):179

Department of General Surgery of Wolski Hospital, Warsaw, Poland.

Download full-text PDF


Still can't find the full text of the article?

Sign up to send a request to the authors directly.
January 2014
8 Reads

Publication Analysis

Top Keywords

stewart-treves syndrome

Similar Publications

Pigmentation on Gingiva: A Diagnostic Dilemma.

Int J Periodontics Restorative Dent 2018 Jan/Feb;38(1):137-140

Pigmentation on gingiva can be physiologic or pathologic. Gingival pigmentation is present from birth in certain individuals. However, sudden occurrence of pigmentation suggests some systemic association. Read More

View Article
October 2018
20 Reads
1.01 Impact Factor

Thyroid Allostasis-Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming.

Front Endocrinol (Lausanne) 2017 20;8:163. Epub 2017 Jul 20.

Medical Department I, Endocrinology and Diabetology, Bergmannsheil University Hospitals, Ruhr University of Bochum, Bochum, Germany.

The hypothalamus-pituitary-thyroid feedback control is a dynamic, adaptive system. In situations of illness and deprivation of energy representing type 1 allostasis, the stress response operates to alter both its set point and peripheral transfer parameters. In contrast, type 2 allostatic load, typically effective in psychosocial stress, pregnancy, metabolic syndrome, and adaptation to cold, produces a nearly opposite phenotype of predictive plasticity. Read More

View Article
July 2017
52 Reads
8 PubMed Central Citations(source)

Gβγ Pathways in Cell Polarity and Migration Linked to Oncogenic GPCR Signaling: Potential Relevance in Tumor Microenvironment.

Mol Pharmacol 2016 Nov 16;90(5):573-586. Epub 2016 Sep 16.

Departments of Pharmacology (J.V.-P., R.D.C.-V.) and Cell Biology (G.R.-C.). CINVESTAV-IPN, Mexico City, and Department of Pharmacology (I.B.-V.), School of Medicine, UABC, Mexicali, B.C., Mexico

Cancer cells and stroma cells in tumors secrete chemotactic agonists that exacerbate invasive behavior, promote tumor-induced angiogenesis, and recruit protumoral bone marrow-derived cells. In response to shallow gradients of chemotactic stimuli recognized by G protein-coupled receptors (GPCRs), Gβγ-dependent signaling cascades contribute to specifying the spatiotemporal assembly of cytoskeletal structures that can dynamically alter cell morphology. This sophisticated process is intrinsically linked to the activation of Rho GTPases and their cytoskeletal-remodeling effectors. Read More

View Article
November 2016
10 Reads
1 PubMed Central Citation(source)
4.13 Impact Factor

Raman Spectroscopy of cultural heritage Materials: Overview of Applications and New Frontiers in Instrumentation, Sampling Modalities, and Data Processing.

Top Curr Chem (Cham) 2016 Oct 22;374(5):62. Epub 2016 Aug 22.

Sorbonne Universités, UPMC Université Pierre et Marie Curie-Paris 6, MONARIS "de la Molécule aux Nano-objets: Réactivité, Interactions et Spectroscopies", UMR 8233, UPMC/CNRS, 4 Place Jussieu, Paris Cedex 05, 75252, France.

Rooted in the long tradition of Raman spectroscopy of cultural heritage materials, in this work we provide a personal perspective on recent applications and new frontiers in sampling modalities, data processing, and instrumentation. Read More

View Article
October 2016
22 Reads

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Lancet Oncol 2012 Oct 4;13(10):1011-9. Epub 2012 Sep 4.

University of Colorado Denver, Aurora, CO, USA.

Background: ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study.

Methods: In this phase 1 study, patients with ALK-positive stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles. Read More

View Article
October 2012
12 Reads
318 PubMed Central Citations(source)
24.69 Impact Factor